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Aims To evaluate efﬁcacy and safety of RLY5016 (a non-absorbed, orally administered, potassium [K
+]-binding polymer) on
serum K
+ levels in patients with chronic heart failure (HF) receiving standard therapy and spironolactone.
Methods
and results
One hundred and ﬁve patients with HF and a history of hyperkalaemia resulting in discontinuation of a renin–
angiotensin–aldosterone system inhibitor/blocker and/or beta-adrenergic blocking agent or chronic kidney disease
(CKD) with an estimated glomerular ﬁltration rate of ,60 mL/min were randomized to double-blind treatment
with 30 g/day RLY5016 or placebo for 4 weeks. Spironolactone, initiated at 25 mg/day, was increased to
50 mg/day on Day 15 if K
+ was ≤5.1 mEq/L. Endpoints included the change from baseline in serum K
+ at the
end of treatment (primary); the proportion of patients with hyperkalaemia (K
+ .5.5 mEq/L); and the proportion
titrated to spironolactone 50 mg/day. Safety assessments included adverse events (AEs) and clinical laboratory
tests. RLY5016 (n ¼ 55) and placebo (n ¼ 49) patients had similar baseline characteristics. At the end of treatment,
compared with placebo, RLY5016 had signiﬁcantly lowered serum K
+ levels with a difference between groups of
20.45 mEq/L (P , 0.001); a lower incidence of hyperkalaemia (7.3% RLY5016 vs. 24.5% placebo, P ¼ 0.015); and
a higher proportion of patients on spironolactone 50 mg/day (91% RLY5016 vs. 74% placebo, P ¼ 0.019). In patients
with CKD (n ¼ 66), the difference in K
+ between groups was 20.52 mEq/L (P ¼ 0.031), and the incidence of hyper-
kalaemia was 6.7% RLY5016 vs. 38.5% placebo (P ¼ 0.041). Adverse events were mainly gastrointestinal, and mild or
moderate in severity. Adverse events resulting in study withdrawal were similar (7% RLY5016, 6% placebo). There
were no drug-related serious AEs. Hypokalaemia (K
+ ,3.5 mEq/L) occurred in 6% of RLY5016 patients vs. 0% of
placebo patients (P ¼ 0.094).
Conclusion RLY5016 prevented hyperkalaemia and was relatively well tolerated in patients with HF receiving standard therapy
and spironolactone (25–50 mg/day) (ClinicalTrials.gov registry identiﬁer: NCT00868439).
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The use of aldosterone antagonists (AAs), when combined with
angiotensin converting enzyme inhibitors (ACE-Is) or angiotensin
receptor blockers (ARBs), has been associated with an improve-
ment in survival and a reduction in hospitalizations for heart
failure (HF) patients with chronic severe HF and a reduced left ven-
tricular ejection fraction (HFREF) as well as in patients with HFREF
post-myocardial infarction (MI).
1,2 In addition, multiple renin–
angiotensin–aldosterone system (RAAS) blockers including direct
renin inhibitors may be beneﬁcial in patients with chronic kidney
disease (CKD) and albuminuria, as well as in patients with resistant
hypertension and other cardiovascular disorders.
3–6
However, these agents are associated with an increased inci-
dence of hyperkalaemia, especially in patients with concomitant
CKD.
7–9 Patients with CKD have been shown to have an attenu-
ated ability to excrete K
+.
10 Dietary K
+ intake, use of pharma-
ceutical agents that impair the ability to excrete K
+, such as
non-steroidal anti-inﬂammatory drugs or RAAS blocking agents,
can increase serum K
+ to critical levels. Although the incidence
of hyperkalaemia in large-scale randomized trials in HFREF patients
receiving an ACE-I or ARB plus an AA is relatively low,
11 the
patients in such trials were generally pre-selected by criteria that
excluded CKD. In clinical practice where patient selection and
serial monitoring of serum K
+ adheres to the criteria used in
large-scale clinical trials, the incidence of hyperkalaemia is low.
12
However, in clinical practice where patient selection and serial
monitoring of serum K
+ may be less rigorous, the incidence of
hyperkalaemia is increased, at times resulting in kidney failure
and death.
13,14 The potential risks of inducing hyperkalaemia by
multiple RAAS inhibitors/blockers has resulted in the use of less
than target or maximally tolerated doses of these life saving
agents, especially in patients with concomitant CKD.
RLY5016 is a non-absorbed polymer designed to bind K
+ in the
gastrointestinal (GI) tract and thereby reduce serum K
+. The aim
of this study is to determine the efﬁcacy, safety, and tolerability
of RLY5016 in a prospective randomized double-blind pilot study
in patients at risk of developing hyperkalaemia, receiving standard
therapy for HF and who were initiating AA therapy with
spironolactone.
Methods
Patients
Eligible patients were ≥18 years of age, had a history of chronic HF, an
indication to initiate spironolactone therapy, per the investigator’s clini-
cal judgment, a serum K
+ concentration of 4.3–5.1 mEq/L at screening.
In addition, they must have had either (i) CKD [with estimated glomer-
ular ﬁltration rate (eGFR) determined by a local laboratory of
,60 mL/min] and were receiving one or more HF therapies
(ACE-Is, ARBs, beta-blockers); or (ii) a documented history of hyper-
kalaemia that led to discontinuation of therapy with an AA, ACE-I,
ARB, or beta-blocker within 6 months prior to the baseline visit.
Patients were excluded if they had severe GI disorders, major GI
surgery, bowel obstruction, swallowing disorders, signiﬁcant primary
valvular disease, known obstructive or restrictive cadiomyopathy,
uncontrolled or unstable arrhythmia, episode of unstable angina
within 3 months prior to baseline, acute coronary syndrome, transient
ischaemic attack, a QTc value of .500 ms (using Bazett’s correction
formula), recent or anticipated cardiac surgery or intervention,
kidney transplantation or need for transplantation, receiving dialysis
or anticipated need for dialysis during the study, sustained systolic
blood pressure .170 or , 90 mmHg, elevated liver enzymes (more
than three times the upper limit of normal), or any condition that
had the potential to interfere with study compliance or jeopardize
the safety of the patient.
Study protocol
This 4-week, double-blind, randomized, placebo-controlled,
parallel-group study was conducted at 38 centres in the USA,
Germany, the Czech Republic, Poland, the Ukraine, Russia, and
Georgia. All participating sites received approval from their locally
appointed ethics committee (or equivalent); all patients provided
informed written consent, and the study was performed in accordance
with current local and national regulations, the International Confer-
ence on Harmonisation Good Clinical Practice guidelines, and other
applicable requirements governing the conduct of human clinical
trials. The study was registered with ClinicalTrials.gov, with an identi-
ﬁer of NCT00868439.
Patients who completed screening and satisﬁed the eligibility criteria
proceeded to baseline assessments, which included review of medical
and medication histories, a physical examination, including weight,
resting vital signs, and 12-lead electrocardiogram (ECG), determination
of serum K
+ (performed by both local and central laboratories), and
clinical laboratory tests (including serum chemistry, haematology, and
urinalysis); in addition, women of child-bearing potential had a serum
pregnancy test.
Following baseline assessments, patients who continued to meet eli-
gibility criteria were randomized 1:1 to RLY5016 or placebo treatment
in a blinded fashion. Patients were instructed to take 15 g of study drug
orally in the morning and evening (for a total daily dose of 30 g) and to
mix study drug (supplied as a powder) with water or a low-potassium
food prior to administration. Patients were also instructed to start spir-
onolactone at a dose of 25 mg/day. After 2 weeks (i.e. on Day 15), spir-
onolactone was increased to 50 mg/day if the patient’s serum K
+ was
.3.5 to ≤5.1 mEq/L; the dose remained at 25 mg/day if the serum K
+
level was .5.1 to ≤5.5 mEq/L; and patients were discontinued from
the study if their serum K
+ was ≤3.5 or .5.5 mEq/L.
Prohibited medications during the study included polymer-based
drugs, other phosphate or K
+ binders, K
+ sparing medications, anta-
cids, calcium or K
+ supplements, and intravenous cardioactive
medications.
Throughout the 4-week treatment period, assessments of efﬁcacy
and safety were performed routinely. Serum K
+ was monitored at
each clinic visit on Days 3, 7, 14, 17, 21, and 28. Serum chemistry,
body weight, and vital signs were assessed on Days 7, 14, 21, and
28; haematology on Days 14 and 28; and 12-lead ECGs and assess-
ments of concomitant medications and adverse events (AEs) were per-
formed at each clinic visit.
All AEs encountered during the study and through 7 days following
completion of study treatment were recorded.
Clinical endpoints
The primary efﬁcacy endpoint was the mean change of serum K
+ from
baseline to the end of the study (Day 28). Secondary endpoints
included the proportion of patients with serum K
+ .5.5 mEq/L at
any time during the trial and the proportion of patients whose spiro-
nolactone dose could be increased to 50 mg/day. Serum K
+ data
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The safety of RLY5016 was assessed by the incidence of AEs or clini-
cally signiﬁcant changes from baseline in clinical laboratory values, vital
signs, and ECG parameters.
Statistical analysis
A sample size of  100 patients (50 patients per treatment group) was
determined to ensure at least 90 patients (45 patients per treatment
group) would be available with primary efﬁcacy data for analysis.
This sample size had 90% power to detect a difference of 0.7 mEq/L
in the mean change of serum K
+ from baseline to the endpoint [last
observation carried forward (LOCF)] between two treatment
groups. This calculation was based on a two-sided two-sample t-test
with a 1:1 sample size allocation ratio, a standard deviation (SD) of
1 mEq/L, and a signiﬁcance level of a ¼ 0.05.
Efﬁcacy and safety analyses were performed on the modiﬁed
intent-to-treat (mITT) population, deﬁned as all randomized patients
who received study medication and had available efﬁcacy data. All
mITT patients were included in the primary and secondary efﬁcacy
analyses. Baseline measurement was the last available measurement
obtained prior to the start of treatment. The endpoint was obtained
at Day 28 post-treatment or was derived based on the LOCF
method for missing data.
A parallel lines analysis of covariance (ANCOVA) model was used
for the analysis of the primary efﬁcacy measurement. This ANCOVA
model included treatment and region factors, and baseline serum K
+
as a covariate. The least squares (LS) estimate of the mean change in
serum K
+ of each treatment and its 95% conﬁdence interval (CI)
was calculated. In addition, the LS estimate of the difference
between RLY5016 treatment and placebo treatment (RLY5016 treat-
ment minus placebo) and its 95% CI was calculated. Patients from all
study centres were pooled for the analysis of the categorical
outcome data. For the analysis of the dichotomous outcome data, a
two-sample Z-test on two proportions between RLY5016 treatment
and placebo treatment was performed. The difference between two
proportions (RLY5016 treatment minus placebo) and its 95% CI
were calculated. Adverse event analyses were performed for the
safety population, which included all patients who received at least
one dose of study drug. The two-sided Fisher exact test was used to
compare the incidence of AEs between two treatment groups. Statisti-
cal analyses were performed using SAS version 9.1 (SAS Institute Inc.,
Cary, NC, USA).
Results
Patient characteristics
Study data were collected between June 2009 and November
2009. A total of 120 patients were randomized (60 to each treat-
ment group) and 105 patients (63 men and 42 women with a mean
age of 68 years) received at least one dose of study drug (56
received RLY5016 and 49 placebo) (Figure 1). One patient random-
ized to RLY5016 received one dose of study drug but did not
return to the clinic within the protocol-speciﬁed time period and
was therefore not evaluable for efﬁcacy. This patient was excluded
from the mITT population, but included in the safety population.
The two treatment groups were balanced with respect to base-
line characteristics (Table 1). Patients had a history of HF with a
mean duration of just over 4 years, and an ejection fraction of
 40%. Most patients were classiﬁed as NYHA class II or III.
About one-third of patients had diabetes and the baseline eGFR
for all patients was 81 + 33 mL/min (calculated based on assess-
ments by a central laboratory). At baseline, four patients (4%)
had severe renal impairment (eGFR ,30 mL/min) and 28 patients
(27%) had an eGFR ,60 mL/min. Eleven patients (15%) had HF
with preserved ejection fraction (HFPEF; LVEF ≥50%), 5 in
placebo and 6 in the RLY5016 group. Two RLY5016-treated
patients with HFPEF were included due to a history of hyperkalae-
mia that resulted in discontinuation of a RAAS blocker or
beta-adrenergic blocking agent.
At baseline, all but two patients (both in the placebo group)
were receiving a RAAS inhibitor or beta-blocker. Slightly more
than half of the patients were on dual therapy of an ACE-I and a
beta-blocker (60% RLY5016 and 53% placebo), 18% of patients
were on dual therapy with an ARB and a beta-blocker (13%
RLY5016 and 22% placebo), and no patients were on both
ACE-I and ARB. Few patients were on monotherapy alone (11%)
and 3% of patients were on triple therapy (ACE-I, ARB, and beta-
blocker). An equal proportion of patients (74%) received diuretics
(15% thiazide, 57% loop) in both the RLY5016 and placebo groups.
The two placebo patients who were not taking a RAAS or beta-
blocker had a history of hyperkalaemia that required discontinu-
ation of these medications.
Overall, 88 (84%) patients completed the study and 17 (8 in the
RLY5016 group and 9 in the placebo group) prematurely termi-
nated from the study. Reasons for discontinuation were attributed
to AEs (four patients from the RLY5016 group and two from the
placebo group); death (one patient in the placebo group);
protocol-speciﬁed discontinuation criteria (two RLY5016 patients
and three placebo patients); protocol non-compliance (one
RLY5016 patient); investigator decision (one RLY5016 patient);
randomization error (one placebo patient); and elective withdrawal
(one placebo patient). Compliance with study drug and spironolac-
tone was measured by the examination of bottles returned to the
clinic at each visit (every 4–7 days); the compliance was . 97% in
both placebo and active groups.
Efﬁcacy
At baseline, mean serum K
+ values were not different between
treatment groups: 4.69 mEq/L for the RLY5016 group and
4.65 mEq/L for the placebo group (between-group P ¼ 0.664).
At the end of the treatment period, RLY5016 had signiﬁcantly
lowered serum K
+ levels relative to placebo, with a difference
between groups of 20.45 mEq/L (P , 0.001). Following the start
of dosing with spironolactone and study drug on Day 1, serum
K
+ values decreased in patients treated with RLY5016 and
increased in patients on placebo (Figure 2). The difference in
response between treatment groups was statistically signiﬁcant at
every measured time point, starting at Day 3 (2 days after initiation
of study medication) and continuing through Day 28, despite an
increase in spironolactone (from 25 to 50 mg/day) at Day 15. At
Day 28 (the end of treatment), patients in the RLY5016 group
had a mean (LS) change in serum K
+ from baseline of
20.22 mEq/L, whereas patients in the placebo group had a mean
change of +0.23 mEq/L.
At all times during the treatment period, fewer patients in the
RLY5016 treatment group developed hyperkalaemia (with a
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+ value .5.5 mEq/L) compared with placebo (7 vs. 25%, P
¼ 0.015; Table 2). However, more RLY5016-treated patients had
hypokalaemia (K
+ ,3.5 mEq/L) than placebo patients (6 and 0%,
respectively), and signiﬁcantly more RLY5016 patients had K
+
values ,4.0 mEq/L than placebo patients (47 vs. 10%, respectively;
P , 0.001; Table 2). In addition, signiﬁcantly more patients in the
RLY5016 group were able to have their spironolactone dose
increased compared with patients in the placebo group (91 vs.
74%, P ¼ 0.019; Table 2).
In the subset of patients with baseline eGFR ,60 mL/min (15
treated with RLY5016 and 13 placebo), the mean change in
serum K
+ to the end of study was different between treatment
groups (P ¼ 0.031): 20.14 vs. +0.38 mEq/L in the RLY5016 and
placebo groups, respectively (Table 3). Consistent with the analysis
of serum K
+ for all patients, RLY5016-treated patients with a base-
line eGFR ,60 mL/min showed greater reduction in mean serum
K
+ compared with placebo as early as Day 3. The differences in
response between treatment groups reached statistical signiﬁcance
on Day 7, which continued throughout the remainder of the study
despite the fact that more RLY5016 patients received a higher
mean dose of spironolactone compared with placebo patients.
For patients with a baseline eGFR ≥60 mL/min, the mean
change in serum K
+ from baseline to the end of treatment was
also signiﬁcantly different between treatment groups (20.35,
P ¼ 0.001; Table 3).
The incidence of hyperkalaemia in the subgroup of HF patients
with CKD was signiﬁcantly reduced with RLY5016 treatment com-
pared with placebo (P ¼ 0.041 for patients with eGFR ,60 mL/
Figure 1 Patient ﬂow diagram.
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≥60 mL/min was lower with RLY5016 treatment compared with
placebo, although the difference was not signiﬁcant (P ¼ 0.13)
(Table 4). Although not statistically signiﬁcant, 87% of HF patients
with CKD treated with RLY5016 could increase their spironolac-
tone dose compared with 69% of the placebo-treated cohorts
with eGFR ,60 mL/min.
The efﬁcacy results for the subgroups based on baseline
eGFR were estimated from an ANCOVA model that included
treatment, region, baseline eGFR group, GFR group by treat-
ment interaction factors, and baseline value as covariates.
Based on this analysis, for patients with a baseline eGFR ,60
and ≥60 mL/min, there was no signiﬁcant GFR-by-treatment
interaction (P ¼ 0.61).
Among the subset of patients who entered the study under the
criteria of a previous history of hyperkalaemia [22 treated with
RLY5016 and 15 placebo (Table 1)], the difference in the mean
change from baseline to last observation in serum K
+ between
treatment groups was 20.34 and +0.09 mEq/L for the RLY5016
and placebo groups, respectively (P ¼ 0.058) (Table 5). The inci-
dence of hyperkalaemia in this subset was 9.1% in the RLY5016
group vs. 20.0% in the placebo group (P ¼ 0.34).
Safety
Thirty (54%) patients in the RLY5016 treatment group and 15
(31%) in the placebo group experienced at least one AE
(Table 6). The most common AEs were GI disorders (e.g. ﬂatu-
lence, diarrhea, constipation, and vomiting), which were reported
with higher frequency in the RLY5016 group compared with the
placebo group (21 vs. 6%, respectively). The majority of AEs
were graded by the investigator as mild or moderate in intensity.
A similar proportion of patients in each treatment group had an
AE that led to discontinuation of study drug (7% RLY5016, 6%
placebo).
Four patients (two in each treatment group) had an SAE. In the
RLY5016 group, one patient had three SAEs, which included wor-
sening coronary artery disease (CAD), atrial ﬁbrillation, and a
non-ST segment elevation MI; a second patient had worsening
CAD. In the placebo group, one patient had an SAE of knee
gout, and a second patient had sudden cardiac arrest that resulted
in death. None of the SAEs was considered by the investigator to
be study drug related.
There were no clinically meaningful treatment-related changes in
most laboratory tests (e.g. serum chemistry, haematology, and uri-
nalysis). In addition to potassium (Table 2), serum chemistry testing
included evaluation of calcium, iron, magnesium, phosphorous, and
sodium. Signiﬁcant changes were noted for serum K
+ (as antici-
pated) and serum magnesium. Although mean serum magnesium
values were within normal limits, a small but statistically signiﬁcant
decrease from baseline was observed (20.22 vs. 0.01 mg/dL for
the RLY5016 and placebo groups respectively, P , 0.001). Serum
magnesium ,1.8 mg/dL during the treatment period was seen in
13 (24%) RLY5016-treated patients and 1 (2.1%) placebo-treated
patient. Additionally, hypomagnesaemia (serum Mg
2+ ,1.8 mg/
dL) occurred in two of the three hypokalaemic patients (serum
K
+ , 3.5 mEq/L). There was no increase in the incidence of ven-
tricular arrhythmias associated with either the development of
hypokalaemia or hypomagnesaemia in these patients.
Both RLY5016- and placebo-treated patients had signiﬁcant
changes in mean serum creatinine from baseline to the end of
study drug treatment at Day 28: the RLY5016 group had a mean
................................................................................
Table 1 Patient baseline characteristics
Parameter RLY5016
(n 5 55)
Placebo
(n 5 49)
Demographics
Age (years) 68 + 96 8 + 11
Male, n (%) 29 (53) 34 (69)
Caucasian, n (%) 53 (95) 48 (98)
BMI (kg/m
2)2 8 + 62 7 + 4
Cardiac history and parameters
HF duration (years) 5 + 54 + 3
NT-proBNP (pg/mL) 1395 + 1955 2339 + 5432
Median NT-proBNP (pg/mL) 824 756
Left ventricular ejection fraction
(%)
40 + 12 41 + 12
NYHA Class, n (%)
I 2 (4) 1 (2)
II 29 (53) 28 (57)
III 24 (44) 20 (41)
IV 0 (0) 0 (0)
Heart rate (b.p.m.) 70 + 11 70 + 11
Systolic blood pressure (mmHg) 128 + 13 128 + 12
Diastolic blood pressure
(mmHg)
78 + 87 8 + 8
Other factors
History of diabetes, n (%) 15 (27) 18 (37)
eGFR (mL/min) 84 + 35 78 + 32
Medication at randomization
Diuretic 41 (75) 36 (74)
Digitalis glycoside 10 (18) 4 (8)
Anti-platelet 37 (66) 32 (65)
ACE-I 45 (82) 28 (57)
Maximum dose of ACE-I, n (%) 6 (13) 2 (7)
ARB 9 (16) 12 (24)
Maximum dose of ARB, n (%) 4 (44) 1 (8)
b–Blocker 45 (82) 46 (94)
Maximum dose of b-blocker, n (%) 8 (18) 5 (11)
ACE-I, ARB, or b-blocker only 13 (24) 9 (18)
ACE-I or ARB + b-blocker 40 (73) 37 (76)
ACE-I + ARB + b–blocker 2 (4) 1 (2)
No RAAS inhibitors or b-blocker 0 (0) 2 (4)
Entry criteria, n (%)
(1) CKD with eGFR ,60 mL/min 27 (50%) 30 (63%)
(2) History of hyperkalaemia 22 (41%) 15 (31%)
Both (1) and (2) 5 (9%) 3 (6%)
Data are presented as mean + SD unless stated otherwise.
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor
blocker; BMI, body mass index; CKD, chronic kidney disease; eGFR, estimated
glomerular ﬁltration rate; HF, heart failure; NYHA, New York Heart Association;
RAAS, renin–angiotensin–aldosterone system.
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mean increase of 0.16 mg/dL (P ¼ 0.001). The difference
between the two treatment groups was not signiﬁcant
(20.07 mg/dL, P ¼ 0.218). For the subgroup of patients with con-
comitant CKD, neither treatment group had a signiﬁcant change
from baseline serum creatinine, and there was no signiﬁcant differ-
ence between treatment groups. For the subgroup of patients with
a baseline eGFR ≥60 mL/min, the mean change in serum creati-
nine within the RLY5106 group from baseline to the end of
treatment was an increase of 0.10 mg/dL (P ¼ 0.008); the change
in the placebo group was an increase of 0.016 mg/dL (P ¼
0.001); and the difference between groups was not signiﬁcant (P
¼ 0.262). For patients who developed hyperkalaemia in the
placebo group, there was a mean increase in serum creatinine of
0.07 mg/dL, whereas in patients who developed hyperkalaemia in
the RLY5016 group, the mean serum creatinine decreased by
0.05 mg/dL (P ¼ NS compared with placebo).
There were no signiﬁcant changes in mean eGFR from baseline
to the end of treatment at Day 28, either within treatment groups
or between treatment groups (the mean difference between
groups was 1.52 mL/min, P ¼ 0.63). Consistent results were
observed for subgroups based on baseline eGFR (, 60 and
≥60 mL/min). For patients with a baseline eGFR ,60 mL/min,
the difference between treatment groups was 3.31 mL/min (P ¼
0.61), and for patients with a baseline eGFR ≥60 mL/min, the
difference between groups was 1.06 mL/min (P ¼ 0.78).
There were no signiﬁcant changes on blood pressure or heart
rate from baseline to the end of treatment at Day 28 between
treatment groups. Furthermore, there were no clinically meaning-
ful treatment-related changes observed for ECGs or physical
examinations.
Discussion
This ﬁrst prospective, placebo-controlled, double-blind trial of
RLY5016 to prevent hyperkalaemia in chronic HF patients
receiving standard therapy, including an ACE-I or ARB and a
beta-adrenergic blocking agent in addition to spironolactone
25–50 mg/day, demonstrated that RLY5016 signiﬁcantly decreased
Figure 2 Least squares mean (SEM) of last observation carried forward (LOCF) serum potassium for the intent-to-treat population by study
visit on Day 15, the spironolactone dose was increased in patients who had serum K
+ levels ≤5.1 mEq/L. * indicates P , 0.01, and ** indicates
P , 0.001. Note: Data were imputed based on LOCF for seven RLY5016-treated patients and nine placebo-treated patients due to early ter-
mination from the study.
....................................
................................................................................
Table 2 Summary of incidence of hyperkalaemia,
hypokalaemia, hypomagnesaemia, and increase of
spironolactone dose
No. (%) of patients P-value
RLY5016
30 g/day (n 5 55)
Placebo
(n 5 49)
Serum potassium
.5.5 mEq/L
a
4 (7) 12 (25) 0.015
Serum potassium
,4.0 mEq/L
26 (47) 5 (10) ,0.001
Serum potassium
,3.5 mEq/L
3 (6) 0 (0) 0.094
Serum magnesium
,1.8 mg/dL
13 (24) 1 (2) 0.001
Spironolactone dose
increased
50 (91) 36 (74) 0.019
aAt any study visit.
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+, reduced the incidence of hyperkalaemia, and increased
the proportion of patients in whom the dose of spironolactone
could be increased to 50 mg/day. These results were obtained in
patients with HF and concomitant CKD, as well as in patients
with HF and a history of hyperkalaemia requiring prior discontinu-
ation of a RAAS blocking agent.
A 30 g/day dose of RLY5016 signiﬁcantly reduced serum K
+
relative to placebo, with a difference between treatment groups
of 0.45 mEq/L. Furthermore, RLY5016 prevented the development
of hyperkalaemia (serum K
+ .5.5 mEq/L), and allowed a signiﬁ-
cantly greater percentage of patients to be up-titrated from
25 mg/day to 50 mg/day of spironolactone compared with
placebo (91 vs. 74%, Table 2). The signiﬁcant reduction in serum
K
+ in patients randomized to 30 g/day of RLY5016 was observed
within 2 days of initiating treatment and persisted throughout the
4-week course of the study (Figure 2).
In the subgroup of patients with HF and a history of hyperkalae-
mia requiring prior discontinuation of a RAAS blocker, but without
concomitant CKD, the mean increase in serum K
+ and the inci-
dence of hyperkalaemia following administration of spironolactone
25–50 mg/day was relatively low in patients assigned to placebo
(Table 5). The explanation for the relatively small increase in
serum K
+ and low incidence of hyperkalaemia despite adminis-
tration of 25–50 mg/day of spironolactone in these patients is
uncertain. In contrast, in the subgroup of patients with HF and con-
comitant CKD (baseline eGFR ,60 mL/min), the incidence of
hyperkalaemia after receiving spironolactone was 39% among
patients taking placebo compared with 7% among patients taking
RLY5016 (Table 4).
RLY5016 at 30 g/day was relatively well tolerated over the
4-week course of the study. Gastrointestinal side effects, generally
mild or moderate in nature, were the most common side effects
reported and occurred at a higher incidence on RLY5016 com-
pared with placebo (Table 6). Treatment with RLY5016 caused a
6% incidence of hypokalaemia (serum K
+ ,3.5 mEq/L) and a
47% incidence of a serum K
+ ,4.0 mEq/L (Table 2), a difference
of 37% compared with the incidence in the placebo group. A
serum K
+ ,3.5 mEq/L has long been recognized as an important
risk factor for death in patients with HFREF.
15 Recent data have
suggested that a serum K
+ ,4.0 mEq/L, and even a serum K
+
,4.0 but .3.5 mEq/L, may also be associated with an increase
in mortality in patients with HFREF and concomitant CKD.
16
Additionally, hypomagnesaemia (serum Mg
2+ ,1.8 mg/dL)
occurred in 24% of the patients and in two of the three hypokalae-
mic patients (serum K
+ ,3.5 mEq/L). Hypomagnesaemia is associ-
ated with ventricular arrhythmias and may increase mortality risk in
patients with hypokalaemia.
RLY5016 has a novel chemical composition that promotes ion-
ization of the polymeric potassium-binding moiety under pH con-
ditions present along the extent of the GI tract, particularly in the
colon. As a result of this chemical structure, RLY5016 exchanges
monovalent (Na
+) and divalent cations (Ca
2+,M g
2+) through
the length of the GI tract and preferentially binds K
+ in the
colon where the concentration of this cation is substantially
higher than that of Na
+,C a
2+,o rM g
2+.
17,18 The net effect of
RLY5016-potassium binding in the colon is a reduction in serum
K
+ under hyperkalaemic conditions, where increased K
+ secretion
through BK channels represents an adaptive response to elevated
serum K
+.
19
The RLY5016 polymer is synthesized as a 100 mm bead, with
optimized ﬂow and viscosity properties. RLY5016 is not adminis-
tered with a cathartic, has not been associated with the occurrence
of bowel necrosis, and has not been found to interfere with the
absorption of drugs that are commonly administrated to patients
with HF and CKD, with the exception of a 30% reduction in the
bioavailability of valsartan and rosiglitazone in preclinical
co-administration studies in rats (data on ﬁle).
RLY5016 binds soluble potassium in the GI tract, thereby effect-
ing movement of K
+ from the serum into the intestinal lumen and
ultimately reducing total body potassium by increasing fecal potass-
ium excretion. Previous studies have demonstrated that the
relationship between total body potassium and serum K
+ is non-
linear.
20 When serum K
+ exceeds a ‘buffering zone’ in the
normal range (serum K
+ of 4.0–5.0 mEq/L), then relatively small
changes in total body potassium cause exaggerated changes in
...............................................................................................................................................................................
Table 3 Summary of least squares mean change + + + + +SEM from baseline in serum potassium by baseline estimated
glomerular ﬁltration rate
Baseline eGFR (mL/min) N/N (RLY5016/Placebo) RLY5016 30 g/day Placebo Difference (mEq/L) P-value
,60 15/13 20.14+0.15 0.38+0.16 20.52+0.23 0.031
≥60 40/36 20.32+0.07 0.02+0.07 20.35+0.10 0.001
SEM, standard error of least squares mean change.
..........................................
................................................................................
Table 4 Incidence of hyperkalaemia by baseline
estimated glomerular ﬁltration rate
Baseline eGFR (mL/min) No. (%) of patients with
hyperkalaemia (serum
potassium > 5.5 mEq/L) at any
study visit
RLY5016
30 g/day
Placebo P-value
,60 1/15 (6.7) 5/13 (38.5) 0.041
≥60 3/40 (7.5) 7/36 (19.4) 0.125
All patients
(eGFR ¼ 81+33)
4/55 (7.3) 12/49 (24.5) 0.015
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+. Analysis of data from previous RLY5016 preclinical and
clinical studies have shown that a ﬁxed dose of RLY5016 has a
greater serum K
+ reducing effect at higher serum K
+ values than
at lower serum K
+ values (data on ﬁle). Based on the relationship
between serum K
+ and changes in total body K
+ (mEq),
20 it is pre-
dicted that at a serum K
+ of 6.5 mEq/L, a 30 g/day dose of
RLY5016 that provides  25 mEq/day extra excretion of fecal K
+
will reduce serum K
+ to 5.5 mEq/L, whereas at a serum K
+ level
of 4.0 mEq/L the same dose of RLY5016 will reduce serum K
+
to only 3.8 mEq/L. This suggests that RLY5016 may not cause
hypokalaemia in patients with levels of serum K
+ greater than
selected for the present study, such as those with hyperkalaemia.
Given the characteristics of the study, several limitations are
apparent. LVEF was not a criterion for entry and on average, the
patients in this study had less severe HF (and a higher LVEF than
those included in RALES), therefore some of the patients did
not meet current ESC/AHA/ACC-HF guideline recommendations
for initiation of AA treatment. Additionally, the sample size was
relatively small, the duration of the study was limited to 4 weeks
of treatment, and a single dose of RLY5016 was evaluated.
The risk of a serum K
+ .5.5 mEq/L was emphasized by a recent
study of over 245 000 patients in the Veterans Administration
system who had a measurement of serum K
+ and on follow-up
were found to have a signiﬁcantly increased risk of death (with
an odds ratio of 10.32) within 1 day of having a serum K
+
.5.5 mEq/L.
21 While CKD has been shown to be an important
predictor of hyperkalaemia in patients receiving multiple RAAS
blockers, recent studies have found that patients with HF and
normal kidney function, especially those with the NR3C2 215G
genotype, may also develop hyperkalaemia
22 despite the ﬁnding
that serum K
+ tends to decrease with the severity of HF in patients
with normal kidney function.
23 While the acute treatment of
hyperkalaemia associated with ECG changes characteristic of
hyperkalaemia and or ventricular arrhythmias will likely continue
to rely on the use of dialysis and other accepted strategies, the
current results with RLY5016 in patients with HF and CKD
suggest that it may be possible to avoid the need for dialysis in
some patients. Longer term studies with a greater numbers of par-
ticipants will be necessary to determine the long-term efﬁcacy and
tolerability of RLY5016 both for the prevention of hyperkalaemia
as well as its treatment once it occurs. In addition, dose ranging
studies will be required to avoid trading the risks of hyperkalaemia
for those of hypokalaemia and hypomagnesaemia.
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Steering Committee: Stefan D. Anker (Berlin Germany), David
A. Bushinsky (Rochester, NY, USA), Dalane W. Kitzman (Winston-
Salem, NC, USA), Bertram Pitt (Ann Arbor, MI, USA), and Faiez
Zannad (Nancy, France).
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Table 5 Summary of least squares mean change + + + + +SEM from baseline in serum potassium and incidence of
hyperkalaemia by entry criteria of history of hyperkalaemia
Analysis Patients with a history of hyperkalaemia at study entry
RLY5016 30 g/day
(N 5 22)
Placebo
(N 5 15)
Difference
(mEq/L)
P-value
Change from baseline in serum potassium (mEq/L) 20.34 + 0.08 0.09 + 0.10 20.25 + 0.13 0.058
Incidence of hyperkalaemia (serum potassium . 5.5 mEq/L),
n (%)
2 (9.1) 3 (20.0) Not applicable 0.341
SEM, standard error of least squares mean change.
.....................................
................................................................................
Table 6 Safety summary
Safety parameter No. (%) of patients
RLY5016
(N 5 56)
Placebo
(N 5 49)
Any adverse event 30 (54) 15 (31)
Gastrointestinal disorders 12 (21) 3 (6)
Flatulence 4 (7) 0
Diarrhea 3 (5) 1 (2)
Constipation 3 (5) 0
Vomiting 2 (4) 0
Any serious adverse event 2 (4) 2 (4)
Related serious adverse event 0 0
Any adverse event leading to
discontinuation of study drug
4 (7) 3 (6)
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Holland (Northport, NY, USA), David Hotchkiss (Port Charlotte,
FL, USA), Marie Iacona (Buffalo, NY, USA), Irakli Khintibidze
(Tblisi, Georgia), Ivan Ma ´lek (Prague, Czech Republic), Mohammed
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